Motor Neuron Disease

Last updated: November 19, 2025
Table Of Contents

Motor Neuron Disease (MND)

Motor Neuron Diseases (MNDs) are neurodegenerative diseases characterised by progressive selective loss of upper motor neurons (motor cortex and cranial nerve nuclei) and lower motor neurons (anterior horn cells). The diseases are purely motor with sensation remaining intact. Bladder and bowel control and extraocular muscles are conserved. This helps differentiate MND from multiple sclerosis, myasthenia gravis and polyneuropathies. It has an insidious and unrelenting course. Diagnosis is clinical. Co-existing upper motor neuron and lower motor neuron signs can help to make the diagnosis.

The average age of onset is 65 years, with 10% of cases presenting before 45 years of age. Affects males more than females.

As mentioned, it may affect either or both of:

  • Upper motor neurons – originating from the primary motor cortex of the cerebrum and forming the motor spinal tracts
  • Lower motor neurons – originate from cranial nerve motor nuclei in the brainstem and the anterior horn of the spinal cord

Amyotrophic Lateral Sclerosis (ALS), AKA Lou Gehrig’s disease, is a rare disorder characterised by progressive deterioration of both upper motor neurons (of the corticospinal tract) and lower motor neurons.

Definition of terms

TermDefinitionCauses
Bulbar palsyLMN lesion of the nuclei of CN IX – XII in the medulla. Presents with flaccid fasciculating tongue, normal or absent jaw jerk, quiet/hoarse/nasal speech.Motor neuron disease, Guillain-Barre, polio, myasthenia gravis, syringobulbia, brainstem tumours, central pontine myelinosis
Pseudobulbar palsyUMN lesion of CN IX – XII due to bilateral lesions above the mid-pons, e.g. corticobulbar palsy. It is more common than bulbar palsy. Presents with slow tongue movements, slow deliberate speech, increased jaw jerk, increased pharyngeal and palatal reflexes, and pseudobulbar affect.Multiple sclerosis, motorneuron disease, stroke, central pontine myelinolysis
Pyramidal signsDamage to either the corticospinal or corticobulbar tracts cause a pyramidal lesion which present with spasticity, hypereflexia, weakness and a positive Babinski sign.

Clinical patterns of motor neuron disease

Clinical patternDescription
Amyotrophic lateral sclerosis (ALS, 80%)AKA Lou Gerigh’s disease. This is the archetypal MND. It is a rare disorder characterized by progressive deterioration of both upper motor neurons (of the corticospinal tract) and lower motor neurons. It presents with combined UMN and LMN signs. Stephen Hawking’s suffered from this disease.
Progressive bulbar palsy (10 – 20%)This only affects cranial nerve IX – XII. Presents with dysarthria, dysphagia, and tongue muscle wasting and fasciculations. Pyramidal signs may be present.
Progressive muscular atropy (< 10%)Affects anterior horn cells and presents with LMN signs only. Affects distal muscle groups more than proximal. Fasciculations and tendon reflexes are present. Has a better prognosis than ALS.
Primary lateral sclerosis (Rare)Characterised by loss of Betz cells in the motor cortex. Mainly presents with UMN signs, marked spastic leg weakness and pseudobulbar palsy. Has no cognitive decline. Gradually progressive.
  • Etiology
    • Genetic factors: four genes have ben identified to be the cause
      • C9ORF72 – associated with fronto-temporal dementia
      • TARDBP
      • SOD1
      • FUS
    • Environmental factors:
      • Smoking
      • Exposure to heavy metals
      • Exposure to certain pesticides
      • Past history of military service
  • Pathophysiology
    • Involves the progressive degeneration of either/both the upper and/or lower motor neurons due to genetic mutations that lead to:
      • Impaired protein homeostasis
      • Mitochondrial dysfunction
      • Aberrant RNA metabolism
      • Dysregulated vesicle transport
      • Impaired DNA repair
      • Oxidative stress
      • Axonal dysfunction
      • Neuroinflammation
      • Glutamate induced excitotoxicity
    • The above processes culminate in motor neuron injury and ultimately denervation of the target.
  • Patient history
    • Increasing age (> 40 years)
    • Family history (particularly in younger patients)
    • Progressive symptoms
    • Complaints relating to limb and gait (tripping, stumbling, limp, hand fatigue, cramping and stiffness)
    • Symptoms often begin focally then spread progressively to involve muscles through out the body.
    • A patient may present at first with either limb symptoms such as weakness or bulbar symptoms such as slurred speech and difficulty talking.
    • As you take history ensure to ask whether:
      • Presentation is symmetrical or asymmetrical
      • Proximal or distal
      • Upper or lower limb predominance
      • Presence or absence of bulbar symptoms
  • Signs and symptoms
    • Upper motor neuron signs
      • Primitive reflexes e.g. Babinski
      • Hyperreflexia
      • Spasticity
      • Hypertonia
      • Clasp-knife reflex
      • Pronator drift
    • Lower motor neuron signs
      • Fibrillation
      • Fasciculations
      • Hypotonia
      • Hyporeflexia
      • Weakness
    • Signs of cranial nerve palsy
      • Dysarthria (CN V, CN VII, CN IX, CN X, CN XII)
      • Hoarsness (CN X)
      • Dysphagia and choking (CN X and CN XII)
    • Psudobulbar affect (inappropriate and involuntary laughing or crying)
    • Respiratory involvement is a terminal event (primarily presents with type 2 respiratory failure)
  • Amyotrophic lateral sclerosis
    • A majority of patients present with limb symptoms with upper limb weakness being noticed first (classic Charcot ALS) with about 30-50% presenting with bulbar symptoms initially (Bulbar-onset ALS) A small minority will present with respiratory symptoms. Starts with the distal muscles, asymmetrically.
    • Clumsiness – dropping things, falling down
    • Inability to perform fine movements such as writing, turning door knobs, turning keys in doors
    • Fatigue when exercising
    • Impaired gait and imbalance – falls
    • Slurred speech
    • Difficulty swallowing leading to progressive weight loss
    • Breathlessness
    • Symptoms of carbon dioxide retention and hypoxia – headache, confusion, warm hands
    • Behavioural changes such as apathy, personality changes, obsessive behaviour
    • Impaired executive functioning – inability to plan, inattention and poor working memory
    • About 10% present with symptoms of fronto-temporal dementia.
  • Progressive bulbar palsy
    • Slurred speech
    • Difficulty swallowing leading to loss of weight
    • Weakened tongue muscles
  • Progressive muscle atrophy
    • Paralysis of limbs
    • Asymmetric weakness and atrophy of limbs
    • Bulbar involvement is uncommon but can occur
    • Flail arm variant – predominantly upper limb involvement with progressive, proximal to distal weakening of the limb
    • Flail leg variant – progressive, asymmetrical involvement of the lower limbs
    Lateral primary sclerosis
    • Stiff or rigid muscles
    • Dysarthria in a subset of patients
  • Physical exam
    • Gait abnormalities
    • Reduced muscle bulk
    • Weakness of limbs (axial)
    • Positive babinski
    • Upper motor neuron signs
      • Hyperreflexia
      • Spastic weakness
      • Exaggerated jaw jerk to clonus
    • Lower motor neuron signs
      • Areflexia or hyporeflexia
      • Flaccid weakness
      • Muscle wasting
      • Fasciculations
    • Bulbar signs
      • Dysarthria
      • Dysphagia
      • Emotional lability
      • Nasal speech
    • Spilt hand pattern – preferential wasting of the first dorsal interossei and thenar muscles with sparing of the hypothenar muscles
    • Split leg pattern – preferential involvement of the planter flexors with sparing of the dorsiflexors
    • There is no sensory or autonomic involvement
  • Differentials
    • Spinal muscle atrophy: lower motor neurons signs in younger patients or infants. Has a family history
    • Spinal canal stenosis: restricted to particular sensory levels. Features pain or change in sensory funciton
    • Stroke: acute onset and localizes to one limb, unilateral, sensory symptoms may be present.
    • Gullian-Barre syndrome: younger patient with acute onset weakness and hyporeflexia/areflexia. Post-infectious history. CSF analysis shows elevated proteins and absent cells
    • Myasthenia gravis: acute onset with extraocular muscle symptoms, smaller muscles affected more than large muscles. Worsens throughout the day. History of autoimmune disease e..g T1DM.
  • Investigations
    • Electromyography: most accurate diagnostic test
    • Complete blood count
    • Erythrocyte sedimentation rate
    • C-reactive protein
    • Biochemical tests such as Thyroid function tests
    • Creatine kinase – elevated
    • Serum immunoglobulins
    • Serum electrophoresis
    • Nerve conduction studies
    • MRI brain and spine
    • Vitamin B12 and folate levels
    • HIV
    • Lyme serology
    • Lumbar puncture
    • Muscle biopsy
    • Biomarker – specific for ALS
    • Genetic testing to look for mutations in the SOD1, FUS, TARDBP, C9orf72 to predict risk and phenotype
  • Treatment
    • Riluzole: NMDA receptor antagonist and inhibitor of glutamate release. Shown to increase survival
    • Dextromethorphan/quinidine for pseudobulbar affect
    • Baclofen or tizanidine for muscle spasms
    • Oral care, positioning and suctioning for excessive saliva
    • Antimuscarinics and botulinum toxin for excessive saliva
    • Blended food and gastrostomy for dysphagia
    • Exercise and orthotics for spasticity
    • Augmentative and alternative communcation equipment for communication difficulty
    • Palliative care
  • Prognosis
    • Poor
    • < 3 years post onset in 50% of patients
  • Negative prognostic factors
    • Bulbar onset
    • Respiratory onset
    • Cognitive impairment
    • Weight loss
    • Older age at onset
    • Shorter time from developing symptoms to diagnosis

Prognosis according to phenotype

PhenotypeMedian survival time from start of symptoms
Amyotrophic lateral sclerosis2-5 years
Primary lateral sclerosis8-10 years
Progressive muscular atrophy2-4 years
Progressive bulbar palsy6 months-3 years
  • Complications
    • Aspiration pneumonia (most common cause of death)
    • Respiratory failure
    • Difficulty swallowing leading to weight loss, choking and aspiration
    • Inability to walk
    • Prolonged immobilization leading to bed sores, increased risk of deep vein thrombosis and superficial skin infections
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Post Discussion

Your email address will not be published. Required fields are marked *